Cartesian Therapeutics (RNAC) Accumulated Expenses (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Accumulated Expenses of $10.2 million for Q1 2026, up 10.48% year-over-year from $9.2 million in Q1 2025, and up 6.98% quarter-over-quarter from $9.5 million in Q4 2025.
Cartesian Therapeutics (RNAC) Accumulated Expenses (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Accumulated Expenses for 12 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 10.48% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (up 10.48% YoY), while the FY2025 annual figure was $9.5 million, down 21.35% from the prior year.
- Accumulated Expenses grew to $10.2 million in Q1 2026 per RNAC's latest filing, from $9.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $15.6 million in Q4 2023 and bottomed at $7.7 million in Q3 2025.
- Historically, Accumulated Expenses has averaged $10.9 million across 5 years, with a median of $10.2 million in 2026.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 39.56% — and 2024, when it tumbled 30.69%.
- Cartesian Therapeutics' Accumulated Expenses stood at $14.1 million in 2022, then rose by 10.57% to $15.6 million in 2023, then dropped by 22.45% to $12.1 million in 2024, then decreased by 21.35% to $9.5 million in 2025, then gained by 6.98% to $10.2 million in 2026.
- Business Quant data shows RNAC's Accumulated Expenses at $10.2 million in Q1 2026, $9.5 million in Q4 2025, and $7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.14 Mn |
| Mar 31, 2026 | 10.16 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Sep 30, 2025 | 7.70 Mn |
| Jun 30, 2025 | 8.01 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 12.08 Mn |
| Sep 30, 2024 | 9.45 Mn |
| Jun 30, 2024 | 10.95 Mn |
| Mar 31, 2024 | 9.52 Mn |
| Dec 31, 2023 | 15.57 Mn |
| Sep 30, 2023 | 13.64 Mn |
| Jun 30, 2023 | 12.90 Mn |
| Mar 31, 2023 | 9.35 Mn |
| Dec 31, 2022 | 14.08 Mn |
| Sep 30, 2022 | 12.26 Mn |
| Jun 30, 2022 | 12.37 Mn |
| Mar 31, 2022 | 8.89 Mn |
| Dec 31, 2021 | 10.53 Mn |
| Sep 30, 2021 | 10.74 Mn |